

carbinoxamine 6 mg tablet
RYVENT

Diagnosis Considered for Coverage:

- Prevention and reduction of symptoms associated with allergies

Coverage Criteria:

For diagnosis listed above:

- Dose not to exceed the FDA label maximum, **and**
- Meets pre-requisite therapy requirement:

PLUS Plan	Medical rationale provided why patient is unable to use the carbinoxamine 4 mg tablet and oral suspension formulations.
STANDARD Plan	Inadequate response, intolerable side effect, or contraindication to cypheptadine.

For brand-name Ryvent:

- Meets above coverage criteria for generic, **and**
- Allergic or intolerable side effect to the generic formulation.

Effective: 1/01/2021